Application of small molecule FPR1 antagonists in the treatment of cancers

• Published in: Scientific reports Vol. 10; no. 1; p. 17249
• Main Authors: Ahmet, Djevdet S., Basheer, Haneen A., Salem, Anwar, Lu, Di, Aghamohammadi, Amin, Weyerhäuser, Patrick, Bordiga, Andrea, Almeniawi, Juman, Rashid, Sabah, Cooper, Patricia A., Shnyder, Steven D., Vinader, Victoria, Afarinkia, Kamyar
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 14.10.2020
• Subjects: 631/67/1059; 631/67/2195; 631/67/322; 631/67/327; Animals; Cell Line, Tumor; Humanities and Social Sciences; Humans; Mice, Inbred BALB C; multidisciplinary; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - metabolism; Receptors, Formyl Peptide - antagonists & inhibitors; Receptors, Formyl Peptide - genetics; Receptors, Formyl Peptide - metabolism; Science; Science (multidisciplinary); Small Molecule Libraries - administration & dosage

The formylpeptide receptor-1 (FPR1) is a member of the chemotactic GPCR-7TM formyl peptide receptor family, whose principle function is in trafficking of various leukocytes into sites of bacterial infection and inflammation. More recently, FPR1 has been shown to be expressed in different types of ca...